에서 실시간으로 운영 중이에요! 자세히 알아보기

ImmuCell

ICCC

시가총액 US$9763만

10.75 USD

+0.19

1.8%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

1일

1.8%

5일

10.26%

1개월

11.86%

3개월

-3.41%

6개월

42.57%

연초 이후

81.59%

1년

72%

5년

19.44%

10년

38.17%

소개: ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

직원 수: 73

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 37.5%

중립 62.5%

부정적 0%

ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results

PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the third quarter of 2026.

ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results

SRK Capital 2026 Semi-Annual Portfolio Update

SRK Fund I, LP increased 26.80% during the first half of the year. In contrast, the S&P 500 and the Russell 2000 returned 10.18% and 22.57%, respectively. ImmuCell delivered a strong first quarter in 2026, underscoring the earnings power and cash-flow potential of its core First Defense franchise after the company's strategic exit from Re-Tain. Since divesting its capital-intensive ammunition manufacturing business in April 2025, Outdoor Holding Company has operated as a pure-play, asset-light marketplace through GunBroker.com.

SRK Capital 2026 Semi-Annual Portfolio Update

Zacks Investment Research

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2

ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell Q2 Earnings Call Highlights

ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.

ImmuCell Q2 Earnings Call Highlights

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended June 30, 2026 after the market closes on Thursday, August 13, 2026. The Company is planning to host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the unaudited financial results.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell: First Defense With Better Execution

ImmuCell's main value driver is First Defense. In my view, this is their core franchise and has real commercial momentum across year-round dairy customers. They've also shown improving manufacturing yields and redirected Re-Tain assets towards First Defense's production capacity. My main concern with ICCC is that it's heavily reliant on two main distributors, as well as concentrated on First Defense as its main product.

ImmuCell: First Defense With Better Execution

Zacks Investment Research

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand

ICCC reports an 11.5% rise in preliminary Q2 sales, driven by robust U.S. demand and improved product availability, extending the momentum from its strong Q1 performance.

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the second quarter of 2026. “Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025,” said Timothy Fiori, Chief Financial Officer of ImmuCell.

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.